Clinical trials: Progressive Glioblastoma
Glioblastoma, Gliosarcoma
Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
Primary objectives To determine maxi tolerated dose of Temodar® in combo w O6-benzylguanine administered for 5 consecutive days in pts w progressive/recurrent GBM To characterize toxicity associated w Temodar® in combo w O6-BG…
- Trial name
- NCT00612989
- Testing
- Temodar and O6-Benzylguanine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Duke University
Glioblastoma Multiforme, Glioblastoma - Category
Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
This is a phase II study on the usage of stereotactic Gamma Knife radiosurgery as a boost to the tumor bed border zone in conjunction with the usage of bevacizumab.
- Trial name
- NCT02120287
- Testing
- Bevacizumab, Magnetic Resonance Spectroscopy (MRS), Border Zone Stereotactic Radiosurgery (BZ-SRS)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Ajay Niranjan
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
This phase II trial is studying how well gossypol works in treating patients with progressive or recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00540722
- Testing
- R-(-)-gossypol acetic acid, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent or Progressive Malignant Glioma
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma.
- Trial name
- NCT00539344
- Testing
- ANG1005
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Angiochem Inc
Teratoid Tumor, Atypical, Choroid Plexus Neoplasms
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
This phase I trial studies the side effects and best dose of azurin-derived cell-penetrating peptide p28 (p28) in treating patients with recurrent or progressive central nervous system tumors.
- Conditions
- Teratoid Tumor, Atypical, Choroid Plexus Neoplasms, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01975116
- Testing
- azurin-derived cell-penetrating peptide p28
- Where
- 11 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain Tumor, Brain Tumor, Recurrent
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
- Conditions
- Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Brain Cancer
- Trial name
- NCT00747253
- Testing
- AutoLITT system
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Monteris Medical
Glioblastoma, Glioma
Methimazole in Patients With Progressive Glioblastoma
The purpose of this study is to test the effectiveness, safety, and tolerability of a drug called Methimazole. The investigational drug, Methimazole is not FDA approved for brain tumors, but it is used to treat thyroid illnesses.
- Trial name
- NCT05607407
- Testing
- Methimazole, Recurrent Glioblastoma Surgical Resection, Pharmacodynamic Assays
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
Glioblastoma, Adult
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.
- Trial name
- ROSALIE (NCT04116658)
- Testing
- Multiple dose of EO2401
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 100 people
- Sponsor
- Enterome
Brain Cancer
Safety Study of Afatinib for Brain Cancer
The purpose of this study is to try to determine the maximum safe dose of afatinib that can be administered to people with brain cancer.
- Trial name
- NCT02423525
- Testing
- Afatinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Santosh Kesari
Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4…
- Conditions
- Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma
- Trial name
- NCT06815029
- Testing
- Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
This phase II trial is studying how well giving erlotinib together with sorafenib works in treating patients with progressive or recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00445588
- Testing
- erlotinib hydrochloride, sorafenib tosylate, pharmacological study
- Where
- 9 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00107458
- Testing
- valproic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Neoplasms
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
First in human, open-label, dose escalation (Phase I) and expansion study (Phase 2a) of oral lisavanbulin (BAL101553) in adult patients with advanced solid tumors and adult patients with recurrent or progressive glioblastoma…
- Trial name
- NCT02490800
- Testing
- Lisavanbulin Phase 1 dose escalation portion, Lisavanbulin Phase 2a expansion portion
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 72 people
- Sponsor
- Basilea Pharmaceutica
Progressive Glioblastoma, Recurrent Glioblastoma
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come…
- Trial name
- NCT06325683
- Testing
- Biopsy Procedure, Biospecimen Collection, Lomustine
- Where
- 325 sites in United States
- Volunteers
- 184 people
- Sponsor
- National Cancer Institute (NCI)